logo
Hidden Sensors Reveal Filthy Truth About Handwashing in Hospital Bathrooms

Hidden Sensors Reveal Filthy Truth About Handwashing in Hospital Bathrooms

Gizmodo5 days ago
Here's something that will make you lose just a bit more faith in humanity—or at least reach for some hand wipes. New research shows that even in hospitals, a substantial number of people aren't bothering to wash their hands.
Scientists from the University of Surrey in England led the study, installing sensors near hospital toilet and sink pipes to keep track of people's handwashing. Nearly half of toilet users skipped the sink after flushing, they found. The researchers say more effective strategies are needed to remind and convince people of the importance of handwashing, particularly in high-risk environments like hospitals.
Scientists Capture the Spray From a Flushing Toilet in All Its Disgusting Glory
Previous studies have tried to analyze how rigorous people are about handwashing in hospitals and other settings, but they've been limited. Some have relied on asking people to self-report their hygiene habits, for instance, which might incentivize more than a few to fudge the truth. The researchers decided to take a different approach. They connected sensors to toilet and sink pipes that could objectively and non-intrusively detect if and when they were being used. The sensors work by measuring the temperature in the pipes and nearby air; when either cold or hot water passes through the pipes, the temperature sharply changes relative to its surroundings, indicating use.
The researchers teamed up with the Bispebjerg Hospital in Denmark to conduct their study (aptly named the 'FLUSH. WASH. PROTECT.' study). For 19 weeks, they tracked people's handwashing behaviors at two public restrooms in the hospital, ultimately recording more than 2,600 flushes. Nearly 44% of the time after flushing, people steered clear of handwashing. At times, non-adherence was even worse, with over 60% of people not handwashing during certain weeks. Non-handwashing was also more common at the start and end of the day and during typical meal times. The team released its findings last week on the Open Source Framework.
'People may assume handwashing is second nature by now—especially in hospitals and post-covid-19—but our data paints a different picture,' said lead author Pablo Pereira-Doel, co-leader of the Human Insight Lab at the University of Surrey's Business School, in a statement from the university.
Mosquitoes Have Mixed Feelings About Soap, Study Finds
Low rates of handwashing can, of course, make it easier for doctors, patients, and visitors to inadvertently spread dangerous infections to already vulnerable people, including drug-resistant superbugs. Some studies have suggested that certain interventions, like clear signs, can modestly boost handwashing at hospitals, at least temporarily. But given the results here, it's likely we'll need to do a lot more to consistently improve people's hand hygiene.
'These findings are worrying but not surprising. Even simple behaviors like handwashing can lapse without reinforcement. In hospitals, lapses like these can have serious consequences—for patients and for the wider healthcare system. It's time we moved beyond posters and hand gel stations to more effective behavioral strategies,' said study author Carrie Newlands, Lead for Clinical Skills at the University of Surrey's School of Medicine, in a statement.
In the meantime, I wouldn't blame you (or myself) for avoiding the standard handshake more often. And just in case anyone needs it, here's the proper technique for handwashing, courtesy of the Centers for Disease Control and Prevention.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY
Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY

Yahoo

timean hour ago

  • Yahoo

Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY

BioNTech SE and Pfizer recently received a positive recommendation from the European Medicines Agency for marketing authorization of their COVID-19 vaccine, which likely contributed to Pfizer's share price increase of 8% in the last quarter. The company's advancements in COVID-19 vaccine development, alongside other product-related announcements like the XTANDI and BRAFTOVI trial results, added weight to this upward movement. Despite legal challenges and declining earnings, Pfizer's focus on innovation and strategic partnerships like the one with XtalPi possibly countered broader market moves, which saw a smaller 1% increase in the same period. We've identified 3 warning signs for Pfizer that you should be aware of. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. The recent positive recommendation from the European Medicines Agency for the COVID-19 vaccine developed by BioNTech SE and Pfizer has contributed to an 8% increase in Pfizer's share price over the last quarter. This news may provide a temporary boost to Pfizer's revenue and earnings forecasts, especially as the company continues to innovate amidst legal challenges and declining earnings. The authorization could enhance immediate market confidence in Pfizer's product pipeline, impacting future revenue projections positively. Over the past year, Pfizer experienced a total return of 13.78% including dividends, reflecting a challenging period for shareholders. When compared to the broader US market's return of 17.2% over the same period, Pfizer has underperformed, highlighting investor concerns over competitive pressures and revenue growth prospects. The current share price movement toward the analyst consensus price target of $29.23 suggests a cautiously optimistic outlook among some market participants. Analysts' revenue forecasts reflect potential declines due to increased competition for existing products, yet others anticipate that strategic shifts in research focus, especially in oncology, might mitigate future earnings risks. With a modest increase of 8% in shares largely tied to vaccine authorization, it underscores the uncertainty surrounding longer-term performance relative to bearish analyst expectations. Understand Pfizer's track record by examining our performance history report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@

Sir David Nabarro, WHO's special envoy for Covid-19, dies aged 75
Sir David Nabarro, WHO's special envoy for Covid-19, dies aged 75

Yahoo

time2 hours ago

  • Yahoo

Sir David Nabarro, WHO's special envoy for Covid-19, dies aged 75

Sir David Nabarro, who was the World Health Organisation's (WHO) special envoy for Covid-19, has died aged 75. The WHO's director-general Dr Tedros Adhanom Ghebreyesus said he was 'deeply shocked and saddened by the passing' of Sir David. London-born Sir David worked at the United Nations for 17 years, expanding nutrition programmes to underdeveloped countries and tackling health crises including outbreaks of malaria, bird flu and Ebola, before leaving in 2017. He was appointed as special envoy on Covid-19 for the WHO in 2020 and appeared on news programmes regularly throughout the pandemic, telling Sky News in June 2021 that humanity was going to have to learn how to 'co-exist' with Covid-19. Sir David was knighted at Buckingham Palace in March 2023 for his outstanding contribution to global health. Dr Tedros wrote on X: 'Deeply shocked and saddened by the passing of our dear friend, colleague and WHO Envoy David Nabarro. 'David was a great champion of global health and health equity, and a wise, generous mentor to countless individuals. 'His work touched and impacted so many lives across the world. 'On behalf of WHO, I'm extending our heartfelt condolences to David's family, friends and colleagues. 'Rest in peace, my dear friend. We will dearly miss your expertise, wisdom and kindness.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store